Malignant peripheral nerve sheath tumors: a report from children's oncology group study ARST0332

Infographic · Feb 2026 · 1 min read

In brief

Children's Oncology Group study ARST0332 evaluated risk-adapted treatment for MPNST in 58 patients, combining surgery, radiation, and chemotherapy. Low-risk patients achieved 87% 5-year survival, while metastatic disease had universally poor outcomes regardless of NF-1 status, highlighting the need for novel therapies.

Low-risk MPNST patients achieved 87% 5-year survival with risk-adapted multimodal therapy combining surgery, radiation, and chemotherapy.
Neoadjuvant chemotherapy showed limited efficacy with only 23% objective response rate; 32% progressed during treatment.
Metastatic MPNST had universally poor outcomes (0% 5-year EFS) regardless of treatment approach, requiring novel therapeutic strategies.
NF-1 status did not impact survival outcomes, contrary to some prior reports suggesting worse prognosis in NF-1 patients.
Complete or near-complete surgical resection (R0/R1) was a critical prognostic factor for event-free and overall survival.

Written by the GCMD Library team from the infographic.

A three-column comparison layout with icons representing different surgical procedures. Each column contains statistical data presented with percentage bars and outcome metrics. The design uses a clinical color palette with blue and green accents to differentiate treatment modalities.

Jacquelyn N Crane, Wei Xue, Amira Qumseya, Donald A Barkauskas, Khang Chau, Serena Y Tan, Susan Hiniker, Roshni Dasgupta, Rajkumar Venkatramani, Sheri L Spunt, Aaron R Weiss, Theodore W Laetsch

Background: The cornerstone of the treatment of malignant peripheral nerve sheath tumors (MPNST) is surgical resection. Radiation and chemotherapy are variably employed. The optimal treatment remains uncertain, particularly for unresectable or metastatic disease and patients with neurofibromatosis type-1 (NF-1).

Methods: We present data for fifty-eight patients with newly diagnosed MPNST enrolled on the Children's Oncology Group study ARST0332. Patients were treated with risk-adapted therapy including surgery with or without radiotherapy and ifosfamide and doxorubicin chemotherapy.

Results: Most patients had primary tumors that were greater than 5 cm (86%), deep (95%), and invasive (74%), and 10% had distant metastases. Thirty-two (55%) patients had germline NF-1 and 26 (45%) did not. Thirty-one patients received neoadjuvant therapy and 22 were evaluable for response with 5 (23%) attaining an objective response, 10 (45%) stable disease, and 7 (32%) progressive disease. Estimated 5-year event-free survival (EFS) was 87%, 52% and 0% for the low- (n = 8), intermediate- (n = 44) and high-risk (n = 6) patients, respectively. In univariate analysis, EFS and overall survival (OS) differed by sex, presence or absence of metastatic disease, risk group, and achievement of upfront or delayed R0/R1. There was no difference in EFS or OS based on germline NF-1 status.

Conclusion: The treatment strategy in ARST0332 achieved excellent outcomes for low-risk MPNST. Patients with high risk (metastatic) MPNST have poor outcomes and novel treatments are needed.

The text in the image

Read it at the source ↗